Download PDF
Thromb Haemost 2002; 87(03): 450-458
DOI: 10.1055/s-0037-1613025
Review Article
Schattauer GmbH

Enhancing the Anticoagulant Potency of Soluble Tissue Factor Mutants by Increasing their Affinity to Factor VIIa

Jihong Yang
1   Department of Protein Engineering, Genentech, Inc., South San Francisco, CA
,
Geoffrey F. Lee
1   Department of Protein Engineering, Genentech, Inc., South San Francisco, CA
2   Baxter Hemoglobin Therapeutics, Boulder, CO
,
Markus A. Riederer
3   Preclinical Research Department, F. Hoffmann-LaRoche, Basel, Switzerland
,
Robert F. Kelley
1   Department of Protein Engineering, Genentech, Inc., South San Francisco, CA
› Author Affiliations
Further Information

Publication History

Received 18 July 2001

Accepted after resubmission 29 November 2001

Publication Date:
14 December 2017 (online)

    Permissions and Reprints

Summary

Complexation of factor VIIa (FVIIa) and tissue factor (TF) initiates the extrinsic pathway of blood coagulation. Inappropriate triggering of this pathway has been linked to thrombotic disorders. We have previously shown that a mutant form of soluble tissue factor (sTF, residues 1-219) having Lys165 and Lys166 replaced with alanine residues (hTFAA) gave an antithrombotic effect in a rabbit model of arterial thrombosis. Here we have improved the potency of hTFAA by incorporating amino acid substitutions that increase the affinity of sTF for FVIIa. Phage display has been used to select consensus sequences at two FVIIa-contact regions on sTF, segments 44–50 and 130–140, that individually showed modestly increased (∼2-fold) FVIIa-affinity. These consensus sequences have been combined with other previously selected mutations to generate a series of variants (hTFAA-2, hTFAA-3, and hTFAA-4) having 4 to 10-fold increased FVIIa-binding affinity. Surface plasmon resonance measurements indicate that the increased affinity results mostly from an increase in the association rate constant. All of these variants displayed increased inhibitor potency relative to hTFAA in an assay of Factor X activation catalyzed by the complex of FVIIa with membrane TF. In addition, these affinity improved hTFAA variants are more potent anticoagulants and have increased antithrombotic activity relative to hTFAA in an ex vivo flow chamber model of thrombosis. The potency trend parallels increases in FVIIa-binding affinity; however, the absolute fold increases in potencies are greater than increases in binding affinity, consistent with kinetic studies of the FVIIa-binding event. Through incorporation of 10 amino acid substitutions (hTFAA-3) we have increased the antithrombotic activity of hTFAA by 20-fold.

Keywords

Tissue factor - coagulation factor VIIa - anticoagulant - phage display
 

  • References

  • 1 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-70.
    CrossrefPubMedGoogle Scholar
  • 2 Ruf W, Edgington TS. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J 1994; 08: 385-90.
    CrossrefPubMedGoogle Scholar
  • 3 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8.
    PubMedGoogle Scholar
  • 4 Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25: 4007-20.
    CrossrefPubMedGoogle Scholar
  • 5 Bom VJJ, Bertina RM. The contributions of Ca2+, phospholipids and tissuefactor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochemistry 1990; 265: 327.
    CrossrefPubMedGoogle Scholar
  • 6 Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165-74.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a “Prima Ballerina”. Thromb Haemost 1995; 74: 7-17.
    PubMedGoogle Scholar
  • 8 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Pathol 1989; 134: 1087-97.
    PubMedGoogle Scholar
  • 9 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839.
    CrossrefPubMedGoogle Scholar
  • 10 Nemerson Y, Repke D. Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor. Thromb Res 1985; 40: 351.
    CrossrefPubMedGoogle Scholar
  • 11 Rao LVM, Rapaport SI. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988; 85: 6687-91.
    CrossrefPubMedGoogle Scholar
  • 12 Sakai T, Lund-Hansen T, Paborsky L, Pedersen AH, Kisiel W. Binding of human factors VII and VIIa to a human bladder carcinoma cell line (J82). J Biol Chem 1989; 264: 9980-8.
    PubMedGoogle Scholar
  • 13 Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
    CrossrefPubMedGoogle Scholar
  • 14 Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood 1990; 76: 731-6.
    PubMedGoogle Scholar
  • 15 Di Scipio RG, Hermodson MA, Davie EW. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry 1977; 16: 698-706.
    CrossrefPubMedGoogle Scholar
  • 16 Banner DW, D’Arcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380: 41-6.
    CrossrefPubMedGoogle Scholar
  • 17 Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 1990; 29: 9418-25.
    CrossrefPubMedGoogle Scholar
  • 18 Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989; 09: 2752.
    CrossrefPubMedGoogle Scholar
  • 19 Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, Mehran R, Sharma SK, Nemerson Y, Fuster V, Fallon JT. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Circulation 1996; 94: 3090-7.
    CrossrefPubMedGoogle Scholar
  • 20 Annex BH, Denning SM, Channon KM, Sketch Jr MH, Stack RS, Morrissey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91: 619-22.
    CrossrefPubMedGoogle Scholar
  • 21 Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubmann MB. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94: 1226-32.
    CrossrefPubMedGoogle Scholar
  • 22 Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques. Circulation 1999; 99: 1780-7.
    CrossrefPubMedGoogle Scholar
  • 23 Broze Jr GJ. The Tissue Factor Pathway of Coagulation: Factor VII, Tissue Factor, and Tissue Factor Pathway Inhibitor. In: Haemostasis and Thrombosis. 3rd ed. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. (eds) Ediburgh: Churchill-Livingstone; 1993: 349-77.
    Google Scholar
  • 24 Wilcox JN, Harker LA. Molecular and cellular mechanisms of atherogenesis: Studies of human lesions linked with animal modeling. In: Haemostasis and Thrombosis. 3rd ed. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. (eds) Edinburgh: Churchill Livingstone; 1994: 1139-52.
    Google Scholar
  • 25 Dennis SM, Eigenbrot C, Skelton NJ, Ultsch MH, Santell L, Dwyer MA, O’Connell MP, Lazarus RA. Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature 2000; 404: 456.
    CrossrefPubMedGoogle Scholar
  • 26 Hirsh J, Weitz JI. Thrombosis: New antithrombotic agents. Lancet 1999; 353: 1431-6.
    CrossrefPubMedGoogle Scholar
  • 27 Vlasuk GP. The new anticoagulants: New opportunities, new issues. Arch Pathol Lab Med 1998; 122: 812-4.
    PubMedGoogle Scholar
  • 28 Kirchhofer D, Moran P, Chiang N, Kim J, Riederer MA, Eigenbrot C, Kelley RF. Epitope location on tissue factor determines the anticoagulant potency of monoclonal anti-tissue factor antibodies. Thromb Haemost 2000; 84: 1072-81.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Kelley RF, O’Connell MP, Modi N, Refino CJ, Pater C, Bunting SJ. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 1997; 89: 3219.
    PubMedGoogle Scholar
  • 30 Himber J, Refino CJ, Burcklen L, Roux S, Kirchhofer D. Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig. Thromb Haemost 2001; 85: 475-81.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Kelley RF, Costas KE, O’Connell MP, Lazarus RA. Analysis of the factor VIIa binding site on human tissue factor: effects of tissue factor mutations on the kinetics and thermodynamics of binding. Biochemistry 1995; 34: 10383.
    CrossrefPubMedGoogle Scholar
  • 32 Lowman HB, Wells JA. Monovalent phage display: a method for selecting variant proteins from random libraries. Methods 1991; 03: 205.
    CrossrefPubMedGoogle Scholar
  • 33 Lowman HB. Phage display of peptide libraries on protein scaffolds. Methods in molecular biology: combinatorial peptide library protocols. Cabilly S. ed. Humana Press, Inc.; Totowa, NJ: 1998. 87 249-64.
    Google Scholar
  • 34 Lee GF, Kelley RF. A novel soluble tissue factor variant with an altered factor VIIa binding interface. J Biol Chem 1998; 273: 4149-54.
    CrossrefPubMedGoogle Scholar
  • 35 Sanger F, Nicklen S, Coulsen AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463.
    CrossrefPubMedGoogle Scholar
  • 36 Kunkel TA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci USA 1985; 82: 488-92.
    CrossrefPubMedGoogle Scholar
  • 37 Kirchhofer D, Tschopp TB, Hadvary P, Baumgartner HR. Endothelial cells stimulated with tumor necrosis factor-a express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. J Clin Invest 1994; 93: 2073-83.
    CrossrefPubMedGoogle Scholar
  • 38 Kirchhofer D, Tschopp TB, Baumgartner HR. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. Arterioscler Thromb Vasc Biol 1995; 15: 1098-106.
    CrossrefPubMedGoogle Scholar
  • 39 Orvim U, Barstad M, Stormorken H, Brosstad F, Sakariassen KS. Immunologic quantification of fibrin deposition in thrombi formed in flowing native human blood. Br J Haematol 1996; 95: 389-98.
    CrossrefPubMedGoogle Scholar
  • 40 Wells JA. Additivity of mutational effects in proteins. Biochemistry 1990; 29: 8509-17.
    CrossrefPubMedGoogle Scholar
  • 41 Kirchhofer D, Lipari MT, Moran P, Eigenbrot C, Kelley RF. The tissue factor region that interacts with substrates factor IX and factor X. Biochemistry 2000; 39: 7380-7.
    CrossrefPubMedGoogle Scholar
  • 42 Kirchhofer D, Eigengrot C, Lipari MT, Moran P, Peek M, Kelley RF. The tissue factor region than interacts with Factor Xa in the activation of Factor VII. Biochemistry 2001; 40: 675-82.
    CrossrefPubMedGoogle Scholar
  • 43 Fuentes-Prior P, Iwanaga Y, Huber R, Pagila R, Rumennik G, Seto M, Morser J, Light DR, Bode W. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature 2000; 404: 518-25.
    CrossrefPubMedGoogle Scholar